ConductScience.org, home
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
API referenceFor AI assistants

Trial · NCT02869438

Results by group124

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 124

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1Benra 30 mgDay 280.21Standard Deviation 0.335Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1PlaceboDay 280.132Standard Deviation 0.316Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1Benra 30 mgDay 560.22Standard Deviation 0.367Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1PlaceboDay 560.203Standard Deviation 0.349Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1Benra 30 mgDay 840.209Standard Deviation 0.344Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1PlaceboDay 840.149Standard Deviation 0.366Liter
Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)Benra 30 mg-0.415Standard Deviation 0.609Liter
Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)Placebo-0.208Standard Deviation 0.528Liter
Percent Change From Baseline to End of Treatment in Eosinophils CountsBenra 30 mg-88.55Full Range -100 to -12.5Percent change
Percent Change From Baseline to End of Treatment in Eosinophils CountsPlacebo11.55Full Range -91.4 to 833.3Percent change
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1Benra 30 mgDay 30.104Standard Deviation 0.223Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1PlaceboDay 30.081Standard Deviation 0.269Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1Benra 30 mgDay 70.125Standard Deviation 0.229Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1PlaceboDay 70.081Standard Deviation 0.263Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1Benra 30 mgDay 140.126Standard Deviation 0.3Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1PlaceboDay 140.1Standard Deviation 0.287Liter
Change From Baseline to Post Baseline for Pre-BD FVCBenra 30 mgDay 30.122Standard Deviation 0.247Liter
Change From Baseline to Post Baseline for Pre-BD FVCPlaceboDay 30.11Standard Deviation 0.267Liter
Change From Baseline to Post Baseline for Pre-BD FVCBenra 30 mgDay 70.138Standard Deviation 0.277Liter
Change From Baseline to Post Baseline for Pre-BD FVCPlaceboDay 70.099Standard Deviation 0.292Liter

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02869438/results

API referenceFor AI assistants